David R Sibley

List of Publications by Year
in descending order

101 papers	3,059 citations	218677 26 h-index	168389 53 g-index
105 all docs	105 docs citations	105 times ranked	2794 citing authors

#	Article	IF	Citations
1	Time will tell. Reply to â€œComments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.â€•by Chen et al.. Molecular Psychiatry, 2022, 27, 1863-1865.	7.9	3
2	Establishing an RNA interference (RNAi) screen for neuroprotection of dopaminergic neurons in Caenorhabditis elegans models of Parkinsonâ€™s disease. FASEB Journal, 2022, 36, .	0.5	0
3	Characterization and Chemical Optimization of the D2 Dopamine Receptorâ€Selective Antagonist, ML321, Identifies Lead Compounds for the Clinical Treatment of Neuropsychiatric Disorders. FASEB Journal, 2022, 36, .	0.5	0
4	Pharmacological actions of a novel and highly selective D3 dopamine receptor agonist, ML417, in a rodent model of Parkinsonâ€™s disease. FASEB Journal, 2022, 36, .	0.5	0
5	Structureâ€“Activity Relationships of a Negative Allosteric Modulator of the D3 Dopamine Receptor and Investigation of its Binding Site. FASEB Journal, 2022, 36, .	0.5	0
6	G proteinâ€coupled receptor kinases regulate &[beta]â€arrestin interactions with the D2 dopamine receptor in an isoformâ€specific manner and in the absence of direct receptor phosphorylation. FASEB Journal, 2022, 36, .	0.5	0
7	Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Molecular Psychiatry, 2022, 27, 4144-4156.	7.9	15
8	Development of pyrimidone D1 dopamine receptor positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2021, 31, 127696.	2.2	6
9	Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Translational Psychiatry, 2021, 11, 59.	4.8	50
10	Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Molecular Psychiatry, 2021, 26, 6704-6722.	7.9	139
11	Dopamine D5 receptor-mediated decreases in mitochondrial reactive oxygen species production are cAMP and autophagy dependent. Hypertension Research, 2021, 44, 628-641.	2.7	13
12	Optimization of ML321: a D ₂ dopamine receptorâ€selective antagonist for the treatment of neuropsychiatric disorders. FASEB Journal, 2021, 35, .	0.5	0
13	Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduction and Targeted Therapy, 2021, 6, 205.	17.1	8
14	G proteinâ€coupled receptor kinase 2 can enhance Î²â€arrestin recruitment to the D ₂ dopamine receptor in the absence of receptor phosphorylation. FASEB Journal, 2021, 35, .	0.5	0
15	Development of a dopaminergic neurodegeneration assay using laser cytometry of Caenorhabditis elegans models of Parkinson's disease. FASEB Journal, 2021, 35, .	0.5	0
16	Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D₂Dopamine Receptor. Molecular Pharmacology, 2021, 100, 372-387.	2.3	14
17	New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry, 2020, 25, 2070-2085.	7.9	55
18	Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D₃ Dopamine Receptor. ACS Chemical Neuroscience, 2020, 11, 3309-3320.	3.5	13

#	Article	IF	Citations
19	Ligand with Two Modes of Interaction with the Dopamine D₂ Receptorâ€"An Induced-Fit Mechanism of Insurmountable Antagonism. ACS Chemical Neuroscience, 2020, 11, 3130-3143.	3.5	8
20	The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia. Scientific Reports, 2020, 10, 2542.	3.3	17
21	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D₃ Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567.	6.4	15
22	A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. Science Signaling, 2020, 13, .	3.6	31
23	High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications, 2019, 10, 4627.	12.8	128
24	A Mechanism Linking Two Known Vulnerability Factors for Alcohol Abuse: Heightened Alcohol Stimulation and Low Striatal Dopamine D2 Receptors. Cell Reports, 2019, 29, 1147-1163.e5.	6.4	20
25	Dopamine D₄ Receptor-Selective Compounds Reveal Structureâ€"Activity Relationships that Engender Agonist Efficacy. Journal of Medicinal Chemistry, 2019, 62, 3722-3740.	6.4	20
26	Novel Dopamine D4 Receptorâ€Selective Compounds Reveal Structureâ€Activity Relationships that Engender Agonist Efficacy. FASEB Journal, 2019, 33, lb40.	0.5	0
27	G proteinâ€coupled receptor kinases can enhance betaâ€arrestin recruitment to the D 2 dopamine receptor in the absence of receptor phosphorylation. FASEB Journal, 2019, 33, 502.1.	0.5	0
28	Identification of an agonist binding site motif that regulates biased signaling of GPCRs through altered conformations of intracellular loop 2. FASEB Journal, 2019, 33, 503.4.	0.5	0
29	Comparative Pharmacology and Structureâ€"Activity Relationships of D1 Dopamine Receptor Positive Allosteric Modulators. FASEB Journal, 2019, 33, 503.2.	0.5	0
30	Identification of a Novel Negative Allosteric Modulator of the D3 Dopamine Receptor. FASEB Journal, 2019, 33, 503.3.	0.5	0
31	Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. Cellular Signalling, 2018, 41, 75-81.	3.6	46
32	A new era of rationally designed antipsychotics. Nature, 2018, 555, 170-172.	27.8	7
33	Identification of Positive Allosteric Modulators of the D₁ Dopamine Receptor That Act at Diverse Binding Sites. Molecular Pharmacology, 2018, 94, 1197-1209.	2.3	35
34	Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. Frontiers in Synaptic Neuroscience, 2018, 10, 2.	2.5	14
35	The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors. PLoS Computational Biology, 2018, 14, e1005948.	3.2	19
36	Identification of Structural Elements that Regulate Signaling Bias in D2-like Dopamine Receptors. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY20-1.	0.0	0

#	Article	IF	Citations
37	Identification of residues in the fifth transmembrane-spanning domain of the D2-like dopamine receptors that engender signaling bias. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-119.	0.0	0
38	Investigating the Interactions of GRK2 with a Gâ€protein Signalingâ€Biased D 2 Dopamine Receptor. FASEB Journal, 2018, 32, 827.13.	0.5	0
39	Discovery and characterization of a novel series of D2 dopamine receptorâ€selective antagonists though iterative chemistry of a BET bromodomain inhibitor. FASEB Journal, 2018, 32, 827.1.	0.5	0
40	Characterization of the novel antiâ€cancer therapeutic ONC201 and related analogs as nonâ€competitive antagonists of the D 2 dopamine receptor. FASEB Journal, 2018, 32, 827.10.	0.5	1
41	Identification and Characterization of ML321: A Novel and Selective D 2 Dopamine Receptor Antagonist with Predicted Atypical Antipsychotic Properties. FASEB Journal, 2018, 32, 827.5.	0.5	0
42	Evidence for a Stereoselective Mechanism of Action for Nonâ€competitive Antagonism of the D3 Dopamine Receptor by Extendedâ€Length Bitopic Ligands. FASEB Journal, 2018, 32, 827.12.	0.5	0
43	Positive Allosteric Modulators of the D 1 Dopamine Receptor Act at Diverse Binding Sites. FASEB Journal, 2018, 32, 827.8.	0.5	1
44	In vivo Behavioral Characterization of ML417, a Novel D 3 Dopamine Receptorâ€selective Agonist. FASEB Journal, 2018, 32, 827.4.	0.5	0
45	Identification of Residues in the Fifth Transmembraneâ€Spanning Domain of the D2â€like Dopamine Receptors that Engender Signaling Bias. FASEB Journal, 2018, 32, 827.11.	0.5	0
46	Characterization of a Novel Series of D4 Dopamine Receptor Ligands Reveals Structureâ€Activity Relationships for Selective Partial Agonists. FASEB Journal, 2018, 32, 827.6.	0.5	0
47	Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D₃ Receptor (D₃R). Journal of Medicinal Chemistry, 2017, 60, 1478-1494.	6.4	44
48	The Dopamine D5 Receptor Is Involved in Working Memory. Frontiers in Pharmacology, 2017, 8, 666.	3.5	15
49	Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D₂/D₃ Receptor Agonist Selectivity. Journal of Medicinal Chemistry, 2016, 59, 2973-2988.	6.4	33
50	Identification of G Protein-Biased Agonists That Fail To Recruit Î²-Arrestin or Promote Internalization of the D1 Dopamine Receptor. ACS Chemical Neuroscience, 2015, 6, 681-692.	3.5	53
51	Structural basis for Na⁺-sensitivity in dopamine D2 and D3 receptors. Chemical Communications, 2015, 51, 8618-8621.	4.1	34
52	PNA-Based Multivalent Scaffolds Activate the Dopamine D₂ Receptor. ACS Medicinal Chemistry Letters, 2015, 6, 425-429.	2.8	13
53	Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. European Neuropsychopharmacology, 2015, 25, 1448-1461.	0.7	20
54	Dopamine D1-like receptors regulate the Î±1A-adrenergic receptor in human renal proximal tubule cells and D1-like dopamine receptor knockout mice. American Journal of Physiology - Renal Physiology, 2014, 307, F1238-F1248.	2.7	7

#	Article	IF	Citations
55	Discovery, Optimization, and Characterization of Novel D₂ Dopamine Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2014, 57, 3450-3463.	6.4	27
56	Discovery and Characterization of a G Proteinâ€"Biased Agonist That Inhibits Î²-Arrestin Recruitment to the D2 Dopamine Receptor. Molecular Pharmacology, 2014, 86, 96-105.	2.3	74
57	Identification of a novel, highly potent D3 dopamine receptorâ€selective agonist (662.8). FASEB Journal, 2014, 28, 662.8.	0.5	0
58	Investigation of the D 1 â€Ð 2 dopamine receptor heteromer reveals a complex signaling mechanism not limited to G q protein activation. FASEB Journal, 2013, 27, 881.1.	0.5	0
59	Identification of substituted benzazepines as functionally selective ligands of the D 1 dopamine receptor. FASEB Journal, 2013, 27, 655.3.	0.5	0
60	Medication discovery for addiction: Translating the dopamine D3 receptor hypothesis. Biochemical Pharmacology, 2012, 84, 882-890.	4.4	116
61	Buspirone is a potent antagonist at D 3 and D 4 Dopamine Receptors and attenuates the reinforcing effects of cocaine in a primate model. FASEB Journal, 2012, 26, 661.4.	0.5	0
62	N-(3-Fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as Selective Dopamine D3 Receptor Ligands: Critical Role of the Carboxamide Linker for D3 Receptor Selectivity. Journal of Medicinal Chemistry, 2011, 54, 3581-3594.	6.4	64
63	Lipid rafts and membrane cholesterol are involved in regulating D2 dopamine receptor signaling. FASEB Journal, 2010, 24, 584.1.	0.5	0
64	G Protein-coupled Receptor Kinase-2 Constitutively Regulates D2 Dopamine Receptor Expression and Signaling Independently of Receptor Phosphorylation. Journal of Biological Chemistry, 2009, 284, 34103-34115.	3.4	67
65	G Protein-coupled Receptor Kinase-mediated Phosphorylation Regulates Post-endocytic Trafficking of the D2 Dopamine Receptor. Journal of Biological Chemistry, 2009, 284, 15038-15051.	3.4	83
66	Pharmacological characterization of 2â€methoxyâ€Nâ€propylnorapomorphine's interactions with D₂ and D₃ dopamine receptors. Synapse, 2009, 63, 462-475.	1.2	34
67	Arrestin3 mediates D₂ dopamine receptor internalization. Synapse, 2009, 63, 621-624.	1.2	32
68	Characterization of sorting nexinâ€25, a D 1 and D 2 dopamine receptor interacting protein that regulates receptor expression and trafficking in HEK293 cells. FASEB Journal, 2009, 23, 942.1.	0.5	0
69	Alterations in D2 dopamine receptor internalization in the presence of the Na+/K+â€ATPase. FASEB Journal, 2009, 23, 938.5.	0.5	0
70	Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling. Neuropharmacology, 2008, 54, 1051-1061.	4.1	45
71	Dopamine receptor interacting proteins: unraveling the receptor signalplex. FASEB Journal, 2008, 22, 726.3.	0.5	1
72	Sorting nexinâ€25, a novel member of the dopamine receptor signalplex, upâ€regulates D 1 and D 2 dopamine receptor expression in HEK293 cells. FASEB Journal, 2007, 21, A423.	0.5	4

#	Article	IF	Citations
73	Reciprocal modulation of function between the D ₁ and D ₂ dopamine receptors and the Na ⁺ /K ⁺ â€ATPase, a novel member of the dopamine receptor signalplex. FASEB Journal, 2007, 21, A423.	0.5	0
74	D5 dopamine receptor regulation of Cu/Zn SOD expression and activity in D5 receptor deficient mice. FASEB Journal, 2006, 20, A309.	0.5	0
75	The Role of Phosphorylation in D1 Dopamine Receptor Desensitization. Journal of Biological Chemistry, 2004, 279, 7999-8010.	3.4	94
76	D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 ï¿½ mesencephalon hybrid cell (MES-23.5) via distinct G proteins. Synapse, 1999, 31, 108-118.	1.2	27
77	Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. , 1997, 26, 400-414.		52
78	Agonist-induced morphologic decrease in cellular d1A dopamine receptor staining. Synapse, 1997, 27, 313-321.	1.2	29
79	Zinc Allosterically Modulates Antagonist Binding to Cloned D₁ and D₂ Dopamine Receptors. Journal of Neurochemistry, 1997, 68, 1990-1997.	3.9	68
80	D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse, 1996, 24, 156-164.	1.2	39
81	[3H]7-OH-DPAT is capable of labeling dopamine D2 as well as D3 receptors. European Journal of Pharmacology, 1995, 272, R1-R3.	3.5	70
82	Molecular Cloning of a Novel G Proteinâ€Coupled Receptor Related to the Opiate Receptor Family. Journal of Neurochemistry, 1995, 64, 34-40.	3.9	216
83	Localization of D₂ dopamine receptors in vertebrate retinae with antiâ€peptide antibodies. Journal of Comparative Neurology, 1993, 331, 469-481.	1.6	72
84	Molecular biology of dopamine receptors. Trends in Pharmacological Sciences, 1992, 13, 61-69.	8.7	890
85	Yeast as a Model System for Studying Glucose Transport. , 0, , 19-36.		11
86	Measuring and Modeling the Spatiotemporal Profile of GABA at the Synapse. , 0, , 259-275.		24
87	Families of Transporters and Their Classification. , 0, , 1-17.		10
88	Methanethiosulfonate Reagent Accessibility Studies, Cysteine-Scanning Mutagenesis, Protein Overexpression, and Functional Reconstitution: A Strategy for Studying the Structure/Function Relationships within the Mitochondrial Citrate Transport Protein. , 0, , 143-159.		0
89	Amperometric Recording of Amphetamine-Induced Dopamine Efflux. , 0, , 191-201.		0
90	Imaging Monoamine Transporters in the Brain. , 0, , 239-257.		0

#	Article	IF	Citations
91	Peptide Mapping of Dopamine Transporter Ligand and Substrate Interaction Sites. , 0, , 161-177.		0
92	Transgenic Mice in Monoamine Transporter Research. , 0, , 51-63.		0
93	Chemical Modification Strategies for Structure-Function Studies. , 0, , 125-141.		12
94	Studies of Glial Glutamate Transporters in Hippocampal Microcultures. , 0, , 217-238.		0
95	Methods in Studying the Regulation and Trafficking of Transmembrane Transporters. , 0, , 111-123.		0
96	Mass Spectrometry of Membrane Transport Proteins. , 0, , 179-189.		0
97	Voltage Clamp and Fluorometric Techniques for Studying Glutamate Transporter Function. , 0, , 203-215.		0
98	Searching for Novel Genetic Variation in Neurotransmitter Transporters. , 0, , 65-87.		0
99	Neurotransmitter Transporters of Drosophila. , 0, , 37-50.		0
100	Nonviral Gene Transfer Allows Up- and Down-Expression of the Brain Serotonin Transporter with Functional Consequences. , 0, , 89-110.		0
101	The show must go on. Reply to â€œDistinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et alâ€•by Insop Shim. Molecular Psychiatry, 0, , .	7.9	0